Medical Design Briefs - November 2024 - 14
Inside the OEM
tion of medtech is only starting and
there is a tremendously positive future
in that area. "
He added that J&J is prioritizing its investments
within the robotics space with
Ottava, VELYS, and MONARCH.
Market: From COVID to the Future
For J&J, the market has normalized.
Schmid said J&J's customers learned a
lot about resiliency through the pandemic.
" We've seen the ability of our
customers to actually do more cases.
The movement of procedures into the
[ambulatory surgery center] environment
has also increased capacity, " he
said. " We still believe that 5-7 percent
market growth, and specifically in orthopedics
roughly 3-5 percent, remains
true. "
Shockwave M5+ effective for both above-the-knee (ATK) and below-the-knee (BTK) endovascular treatments. (Credit:
Shockwave Medical)
with the continued penetration of robotic
procedures. And so that has been
a headwind, " said Schmid. " If you look
at our results in the second quarter, we
declined 1.2 percent. If you actually
neutralize for the impact of the divestiture
of our Acclarent business, which
we made last year, it was roughly flat. We
do see that returning to low single-digit
growth as we look through the back half
of the year.
He emphasized that this is a business
J&J is not giving up on. " One of the biggest
investments we are making across all
of Johnson & Johnson organically is in
our surgical robot in Ottava, and I can
confidently communicate that we are
very much on track to deliver the IDE,
which we said we would achieve by the
end of this year. "
" We're also learning from other
competitors who have entered that
space on what to do and what not to
do, " he said. " We take this launch very
seriously, but we've got something that
we think really differentiates ourselves
from our competitors, - the only soft
tissue robot with an architecture where
the arms are actually built into the table.
We have twin motion, which allows
the arms and the bed to move simultaneously,
which is really important in
complex cases. And what surgeons ab14
solutely
love about Johnson & Johnson
is the quality of our instruments. And
so that robot married with our advanced
instrumentation, we believe, is
going to create competitive advantage
in that market. "
Digital and Robotic Strategy
J&J's success in orthopedics is how the
company marries its best-in-class implants
with a surgical robot, he said. " We've got
VELYS, which was launched two and a
half years ago. It's now available in more
than 21 markets, with more than 70,000
procedures. And the success we're enjoying
now - 9.4 percent growth on our
knees - is a direct result of that marriage
of a great robot with a great implant.
We're seeing the same thing on hips. It's
not just our ACTIS implant, it's ACTIS
with KINCISE, and the VELYS-assisted
solution for hip replacement. "
J&J announced recently that it will
also be entering the spine market with
a robot next year. Schmid said that
presents an opportunity to bring a differentiated
innovation to that space.
" But once again, it's not just the robot
by itself. It's the robot in combination
with our thoracolumbar system, especially
the launch of TriALTIS. We think
that combination is really important.
And we think that, frankly, the digitizawww.medicaldesignbriefs.com
" But
from our perspective, the market
really returned to more normal levels.
I would say we are back to preCOVID
levels. "
Schmid said that the focus for J&J is
to grow Abiomed and Shockwave as
fast as it can. He said he is also excited
about the tuck-in of Laminar, which
was announced in the fourth quarter.
Getting into left atrial appendage provides
a lot of opportunity for competition
in a nearly billion-dollar market.
" V-Wave is another good example.
This is a company that we started investing
in 2017. Initially, we invested in
that business behind our electrophysiology
portfolio. Now that we have a
market leadership position in heart
failure, we're actually aligning that
business in V-Wave with Abiomed, " he
said. " We're starting to create these
fortresses across our
cardiovascular
portfolio. "
As for other exciting opportunities,
Schmid said, " There's no shortage of rumors
out there. We've got our hands full
and are very excited about the portfolio
we've got. We are the only competitor in
cardiovascular with high-growth, highmargin
businesses, and that's what we'd
like to continue. We've gone through a lot
of changes of late as we've now spun off
our consumer business, which is actually
creating much more focus in the businesses
that we've retained in both innovative
medicine and medtech.
This article was written by Sherrie
Trigg, Editor and Director of Content,
Medical Design Briefs. She can be reached
at sherrie.trigg@saemediagroup.com.
Medical Design Briefs, November 2024
https://www.medicaldesignbriefs.com
Medical Design Briefs - November 2024
Table of Contents for the Digital Edition of Medical Design Briefs - November 2024
Medical Design Briefs - November 2024 - Intro
Medical Design Briefs - November 2024 - Sponsor
Medical Design Briefs - November 2024 - COV1a
Medical Design Briefs - November 2024 - COV1b
Medical Design Briefs - November 2024 - COV1
Medical Design Briefs - November 2024 - COV2
Medical Design Briefs - November 2024 - 1
Medical Design Briefs - November 2024 - 2
Medical Design Briefs - November 2024 - 3
Medical Design Briefs - November 2024 - 4
Medical Design Briefs - November 2024 - 5
Medical Design Briefs - November 2024 - 6
Medical Design Briefs - November 2024 - 7
Medical Design Briefs - November 2024 - 8
Medical Design Briefs - November 2024 - 9
Medical Design Briefs - November 2024 - 10
Medical Design Briefs - November 2024 - 11
Medical Design Briefs - November 2024 - 12
Medical Design Briefs - November 2024 - 13
Medical Design Briefs - November 2024 - 14
Medical Design Briefs - November 2024 - 15
Medical Design Briefs - November 2024 - 16
Medical Design Briefs - November 2024 - 17
Medical Design Briefs - November 2024 - 18
Medical Design Briefs - November 2024 - 19
Medical Design Briefs - November 2024 - 20
Medical Design Briefs - November 2024 - 21
Medical Design Briefs - November 2024 - 22
Medical Design Briefs - November 2024 - 23
Medical Design Briefs - November 2024 - 24
Medical Design Briefs - November 2024 - 25
Medical Design Briefs - November 2024 - 26
Medical Design Briefs - November 2024 - 27
Medical Design Briefs - November 2024 - 28
Medical Design Briefs - November 2024 - 29
Medical Design Briefs - November 2024 - 30
Medical Design Briefs - November 2024 - 31
Medical Design Briefs - November 2024 - 32
Medical Design Briefs - November 2024 - 33
Medical Design Briefs - November 2024 - 34
Medical Design Briefs - November 2024 - 35
Medical Design Briefs - November 2024 - 36
Medical Design Briefs - November 2024 - 37
Medical Design Briefs - November 2024 - 38
Medical Design Briefs - November 2024 - 39
Medical Design Briefs - November 2024 - 40
Medical Design Briefs - November 2024 - 41
Medical Design Briefs - November 2024 - 42
Medical Design Briefs - November 2024 - 43
Medical Design Briefs - November 2024 - 44
Medical Design Briefs - November 2024 - 45
Medical Design Briefs - November 2024 - 46
Medical Design Briefs - November 2024 - 47
Medical Design Briefs - November 2024 - 48
Medical Design Briefs - November 2024 - 49
Medical Design Briefs - November 2024 - 50
Medical Design Briefs - November 2024 - COV3
Medical Design Briefs - November 2024 - COV4
https://www.nxtbook.com/smg/techbriefs/25MDB02
https://www.nxtbook.com/smg/techbriefs/25MDB01
https://www.nxtbook.com/smg/techbriefs/24MDB12
https://www.nxtbook.com/smg/techbriefs/24MDB11
https://www.nxtbook.com/smg/techbriefs/24MDB10
https://www.nxtbook.com/smg/techbriefs/24MDB09
https://www.nxtbook.com/smg/techbriefs/24MDB08
https://www.nxtbook.com/smg/techbriefs/24MDB07
https://www.nxtbook.com/smg/techbriefs/24MDB06
https://www.nxtbook.com/smg/techbriefs/24MDB05
https://www.nxtbook.com/smg/techbriefs/24MDB04
https://www.nxtbook.com/smg/techbriefs/24MDB03
https://www.nxtbook.com/smg/techbriefs/24MDB02
https://www.nxtbook.com/smg/techbriefs/24MDB01
https://www.nxtbook.com/smg/techbriefs/23MDB12
https://www.nxtbook.com/smg/techbriefs/23MDB11
https://www.nxtbook.com/smg/techbriefs/23MDB10
https://www.nxtbook.com/smg/techbriefs/23MDB09
https://www.nxtbook.com/smg/techbriefs/23MDB08
https://www.nxtbook.com/smg/techbriefs/23MDB07
https://www.nxtbook.com/smg/techbriefs/23MDB06
https://www.nxtbook.com/smg/techbriefs/23MDB05
https://www.nxtbook.com/smg/techbriefs/23MDB04
https://www.nxtbook.com/smg/techbriefs/23MDB03
https://www.nxtbook.com/smg/techbriefs/23MDB02
https://www.nxtbook.com/smg/techbriefs/23MDB01
https://www.nxtbook.com/smg/techbriefs/techleaders22
https://www.nxtbook.com/smg/techbriefs/22MDB12
https://www.nxtbook.com/smg/techbriefs/22MDB11
https://www.nxtbook.com/smg/techbriefs/22MDB10
https://www.nxtbook.com/smg/techbriefs/22MDB09
https://www.nxtbook.com/smg/techbriefs/22MDB08
https://www.nxtbook.com/smg/techbriefs/22MDB07
https://www.nxtbook.com/smg/techbriefs/22MDB06
https://www.nxtbook.com/smg/techbriefs/22MDB04
https://www.nxtbook.com/smg/techbriefs/techleaders21
https://www.nxtbook.com/smg/techbriefs/22MDB03
https://www.nxtbook.com/smg/techbriefs/22MDB02
https://www.nxtbook.com/smg/techbriefs/22MDB01
https://www.nxtbook.com/smg/techbriefs/21MDB12
https://www.nxtbook.com/smg/techbriefs/21MDB11
https://www.nxtbook.com/smg/techbriefs/21MDB10
https://www.nxtbook.com/smg/techbriefs/21MDB09
https://www.nxtbook.com/smg/techbriefs/21MDB08
https://www.nxtbook.com/smg/techbriefs/21MDB07
https://www.nxtbook.com/smg/techbriefs/21MDB06
https://www.nxtbook.com/smg/techbriefs/21MDB05
https://www.nxtbook.com/smg/techbriefs/21MDB04
https://www.nxtbook.com/smg/techbriefs/21MDB02
https://www.nxtbookmedia.com